Atypical ductal hyperplasia

From Libre Pathology
Jump to navigation Jump to search
The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.
Atypical ductal hyperplasia
Diagnosis in short

Atypical ductal hyperplasia. H&E stain. (WC/Nephron)

LM cytologic and architectural features of low-grade DCIS (equal cell spacing, lumina round, variable architecture (classically cribriform or solid - may be micropapillary or papillary), small nuclei, small indistinct nucleoli); limited extent - either (1) two or less complete ducts, (2) <2 mm in size
LM DDx ductal carcinoma in situ, invasive ductal carcinoma of the breast
Site breast - see non-invasive breast carcinoma

Symptoms none
Prevalence relatively common
Radiology suspicious calcifications
Prognosis benign, increased risk of malignancy
Treatment lumpectomy when found on biopsy, follow-up if on excisional specimen

Atypical ductal hyperplasia, abbreviated ADH, is a benign breast lesion associated with an increased risk of malignancy.

General

  • Molecular studies have shown it is the same thing as low-grade DCIS; thus, some have called for abolition of the term.[1]
  • ADH is considered an indication for a lumpectomy.[2]
    • Two large studies suggest the conversion of an ADH on core biopsy to breast cancer on surgical excision, known as "up-grading", is approximately 30%.[3][4]

Epidemiology:

  • Relative risk of breast cancer, based on a median follow-up of 8 years, in a case control study of US registered nurses, is 3.7.[5]

Microscopic

Features:

  • Cytologic and architectural features of low-grade DCIS.
    • Cell spacing ~ equal.
    • Lumina round.
    • Architecture - classically cribriform or solid; may be micropapillary or papillary.
    • Small nuclei.
      • Small indistinct nucleoli.
  • Limited extent (diagnostic size cutoffs) - either:[6]
    1. < Two complete ducts.
    2. < 2 mm. ‡

DDx:

Notes:

  • High-grade DCIS is not in the DDx of ADH.
  • ‡ 3 mm is used in papillary lesions.[citation needed]

Images

IHC

  • CK5 <20% +ve.
  • ER +ve - diffusely.

See also

References

  1. Ghofrani, M.; Tapia, B.; Tavassoli, FA. (Dec 2006). "Discrepancies in the diagnosis of intraductal proliferative lesions of the breast and its management implications: results of a multinational survey.". Virchows Arch 449 (6): 609-16. doi:10.1007/s00428-006-0245-y. PMID 17058097.
  2. Liberman L, Cohen MA, Dershaw DD, Abramson AF, Hann LE, Rosen PP (May 1995). "Atypical ductal hyperplasia diagnosed at stereotaxic core biopsy of breast lesions: an indication for surgical biopsy". AJR Am J Roentgenol 164 (5): 1111–3. PMID 7717215. http://www.ajronline.org/cgi/pmidlookup?view=long&pmid=7717215.
  3. Deshaies, I.; Provencher, L.; Jacob, S.; Côté, G.; Robert, J.; Desbiens, C.; Poirier, B.; Hogue, JC. et al. (Feb 2011). "Factors associated with upgrading to malignancy at surgery of atypical ductal hyperplasia diagnosed on core biopsy.". Breast 20 (1): 50-5. doi:10.1016/j.breast.2010.06.004. PMID 20619647.
  4. Margenthaler, JA.; Duke, D.; Monsees, BS.; Barton, PT.; Clark, C.; Dietz, JR. (Oct 2006). "Correlation between core biopsy and excisional biopsy in breast high-risk lesions.". Am J Surg 192 (4): 534-7. doi:10.1016/j.amjsurg.2006.06.003. PMID 16978969.
  5. London, SJ.; Connolly, JL.; Schnitt, SJ.; Colditz, GA. (Feb 1992). "A prospective study of benign breast disease and the risk of breast cancer.". JAMA 267 (7): 941-4. PMID 1734106.
  6. Tadrous, Paul.J. Diagnostic Criteria Handbook in Histopathology: A Surgical Pathology Vade Mecum (1st ed.). Wiley. pp. 258. ISBN 978-0470519035.